Dr. Dilek Telci

Dilek Telci is a professor of Molecular Cell Biology in the Department of Genetics and Bioengineering at Yeditepe University. She received her BSc in Biology, MSc in Medical Genetics with Immunology, and PhD in Molecular Cell Biology from Middle East Technical University, Brunel University and Nottingham Trent University, respectively. Following postdoctoral and research associate fellowships at Sabanci and Aston University, she joined the Department of Genetics and Bioengineering at Yeditepe University. The primary focus of Prof.Dr. Telci’s research is on cell adhesion, migration and signalling mechanisms in fibrosis, cancer metastasis, and drug resistance, which is funded by European Union and TUBITAK awarded grants. In 2021, her patent application on the development of a combination therapy to overcome Everolimus resistance in RCC (US 10,918,644 B2) was published.  Her recent papers includes the development of targeted therapies for breast and prostate cancer as well as RCC. Prof.Dr.Dilek Telci’s major scientific contributions and discoveries include: mechanism of tissue transglutaminase (TG2) mediated cell adhesion and integrin trafficking; role of TG2 in the development and metastasis of RCC; development of a combination therapy to overcome Everolimus resistance in RCC; the interplay between TG2 and nitric oxide in the regulation of matrix deposition and degradation; and the role of KLOTHO and TG2 in kidney stone disease.